NF-κB as a therapeutic target in cancer

Trends in Molecular Medicine

Volumn 8, Issue 8, 2002, Pages 385-389

  Orlowski, Robert Z ^a   Baldwin Jr , Albert S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; PACLITAXEL; PROTEASOME INHIBITOR; THALIDOMIDE; TRANSCRIPTION FACTOR; I KAPPA B;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; HUMAN; METASTASIS; REVIEW; ANIMAL; APOPTOSIS; CELL TRANSFORMATION; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; TRANSACTIVATION;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; TRANS-ACTIVATION (GENETICS);

EID: 0036020941     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02375-4     Document Type: Review

References (50)

1. The NF-κB and IκB proteins: New discoveries and insights
2. NF-κB and Rel proteins: Evolutionarily conserved mediators of the immune response
3. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
4. Phosphorylation meets ubiquitination: The control of NF-κB activity
5. Aberrant Rel/NF-κB genes and activity in human cancer
6. Mutations in the IκBα gene in Hodgkin's disease suggest a tumor suppressor role for IκBα
7. The role of Rel/NF-κB proteins in viral oncogenesis and the regulation of viral transcription
8. Role of the IκB kinase complex in oncogenic Ras and Raf-mediated transformation of rat liver epithelial cells
9. Constitutive NF-κB/RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
10. Aberrant NF-κB/Rel expression and the pathogenesis of breast cancer
11. Selective activation of NF-κB subunits in human breast cancer: Potential roles for NF-κB2/p52 and Bcl-3
12. Expression of a dominant mutant IκBα in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo
13. Transcriptional cross-talk between NF-κB and p53
14. Role of NF-κB in p53-mediated programmed cell death
15. Cyclo-oxygenase regulates angiogenesis induced by colon carcinoma cells
16. NF-κB activity correlates with growth, angiogenesis and metastasis of human melanoma cells in nude mice
17. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by NF-κB
18. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastasis
19. Mice deficient in TNFα are resistant to skin carcinogenesis
20. IL-1α promotes NF-κB and AP-1-induced IL-8 expression, cell survival and proliferation in head and neck squamous cell carcinomas
21. The role of TNFα in the pathophysiology of human multiple myeloma: Therapeutic applications
22. NF-κB-induced loss of MyoD mRNA: Possible role in muscle decay and cachexia
23. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
24. Proteasome inhibitors: A novel class of potent and effective antitumor agents
25. Tumor growth inhibition in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
26. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinomaA-549 in nude mice
27. Novel proteasome inhibitor PS-341 inhibits activation of NF-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
28. The role of the ubiquitinproteasome pathwayin apoptosis
29. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IKK
30. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity
31. History of development of arsenic derivatives in cancer therapy
32. NF-κB as a therapeutic target in multiple myeloma
33. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic NF-κB inhibition
34. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
35. NF-κB/IκB signaling pathways may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells
36. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
37. Antitumor activity of thalidomide in refractory multiple myeloma
38. Activity of thalidomide in AIDS-related Kaposi's sarcoma
39. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
40. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
41. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
42. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
43. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells